In the phase III ADRIATIC trial, Imfinzi (durvalumab) showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival for patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, compared to placebo after cCRT.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
